Gerald I. Shulman, M.D., Ph.D., has received a Harrington Scholar-Innovator award from The Harrington Discovery Institute for his work on an oral pill that reversed type 2 diabetes and liver disease in rats. The award provides up to $100,000 over two years—with the possibility of receiving up to $700,000.
As part of the award, Shulman will have the opportunity to work with drug development professionals to bring the new drug, controlled-release mitochondrial protonophore, to market.
About 9.3 percent of the U.S. population suffers from diabetes, according to the Centers for Disease Control and Prevention.
Submitted by John Curtis on January 11, 2016